Lixte Biotechnology Holdings, Inc. (LIXT) financial statements (2020 and earlier)
Company profile
| Business Address |
248 ROUTE 25A EAST SETAUKET, NY 11733 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| SIC | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in thousands)
| 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | 12/31/2013 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 2,599 | 4,273 | 1,306 | 200 | 25 | 44 | 475 | ||
| Cash and cash equivalents | 2,599 | 4,273 | 1,306 | 200 | 25 | 44 | 475 | ||
| Receivables | 14 | ||||||||
| Prepaid expense | 9 | ||||||||
| Other undisclosed current assets | 59 | 52 | 62 | 233 | 573 | 495 | 83 | ||
| Total current assets: | 2,672 | 4,334 | 1,368 | 433 | 598 | 539 | 558 | ||
| Noncurrent Assets | |||||||||
| Prepaid expense | 2 | ||||||||
| Total noncurrent assets: | 2 | ||||||||
| TOTAL ASSETS: | 2,672 | 4,337 | 1,368 | 433 | 598 | 539 | 558 | ||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities, including: | 144 | 195 | 312 | 160 | 159 | 123 | 108 | ||
| Interest and dividends payable | 2 | ||||||||
| Other undisclosed accounts payable and accrued liabilities | 144 | 195 | 312 | 160 | 157 | 123 | 108 | ||
| Due to related parties | 93 | ||||||||
| Other undisclosed current liabilities | 94 | 16 | 61 | 59 | 127 | 58 | 214 | ||
| Total current liabilities: | 238 | 211 | 373 | 219 | 286 | 273 | 322 | ||
| Noncurrent Liabilities | |||||||||
| Total liabilities: | 238 | 211 | 373 | 219 | 286 | 273 | 322 | ||
| Stockholders' equity | |||||||||
| Stockholders' equity attributable to parent, including: | 2,434 | 4,126 | 995 | 215 | 312 | 266 | 236 | ||
| Preferred stock | 3,500 | 3,500 | 3,500 | 3,500 | 1,750 | ||||
| Common stock | 7 | 7 | 6 | 5 | 5 | 5 | 4 | ||
| Additional paid in capital | 26,016 | 25,268 | 20,005 | 17,417 | 17,130 | 15,979 | 13,184 | ||
| Accumulated deficit | (27,089) | (24,649) | (22,515) | (20,707) | (18,572) | (15,718) | |||
| Other undisclosed stockholders' equity attributable to parent | (12,952) | ||||||||
| Total stockholders' equity: | 2,434 | 4,126 | 995 | 215 | 312 | 266 | 236 | ||
| TOTAL LIABILITIES AND EQUITY: | 2,672 | 4,337 | 1,368 | 433 | 598 | 539 | 558 | ||
Income statement (P&L) ($ in thousands)
| 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | 12/31/2013 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues (Revenue, Net) | 200 | |||||||
| Cost of revenue (Cost of Goods and Services Sold) | (25) | (53) | (25) | |||||
| Gross profit: | (25) | 147 | (25) | |||||
| Operating expenses | (2,490) | (2,138) | (1,810) | (2,135) | (2,846) | (2,403) | (1,375) | |
| Other undisclosed operating income | 25 | 53 | 25 | |||||
| Operating loss: | (2,490) | (2,138) | (1,810) | (2,135) | (2,646) | (2,403) | (1,375) | |
| Nonoperating income (Investment Income, Nonoperating) | 50 | 5 | 1 | 0 | 0 | 0 | 0 | |
| Net loss: | (2,440) | (2,133) | (1,808) | (2,135) | (2,646) | (2,403) | (1,375) | |
| Other undisclosed net loss attributable to parent | (206) | (363) | ||||||
| Net loss attributable to parent: | (2,440) | (2,133) | (1,808) | (2,135) | (2,852) | (2,766) | (1,375) | |
| Other undisclosed net loss available to common stockholders, basic | (2) | |||||||
| Net loss available to common stockholders, diluted: | (2,440) | (2,133) | (1,808) | (2,135) | (2,854) | (2,766) | (1,375) | |
Comprehensive Income ($ in thousands)
| 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | 12/31/2013 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (2,440) | (2,133) | (1,808) | (2,135) | (2,646) | (2,403) | (1,375) | |
| Comprehensive loss, net of tax, attributable to parent: | (2,440) | (2,133) | (1,808) | (2,135) | (2,646) | (2,403) | (1,375) | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.